Objective: To compare the effect of a high monounsaturated fatty acid (MUFA) diet and of a control low-fat diet consumed under ad libitum conditions on plasma apolipoprotein (apo) C-III metabolism. Design: Randomized, two-arm parallel dietary trial. Setting: Diets were prepared and consumed at the metabolic kitchen of the Department of Food Sciences and Nutrition, and laboratory analyses were performed at the Institute of Nutraceuticals and Functional Foods at Laval University. Subjects and interventions: Eighteen men were randomly assigned to either the high MUFA diet or the low-fat control diet, which they consumed for 6-7 weeks. Before and after the dietary intervention, subjects received a primed-constant infusion of [5,5,5-D 3 ]-L-leucine for 12 h under constant feeding conditions for the determination of plasma apoC-III kinetics. Results: The high-MUFA diet and the low-fat control diet had no significant impact on plasma apoC-III production rate (PR) or fractional catabolic rate. However, diet-induced variations in plasma apoCIII PR predicted the reduction in plasma triglycerides and apoC-III levels (r ¼ 0.85, Po0.01 and r ¼ 0.73, Po0.05, respectively) in the high MUFA group only. Conclusions: These results suggest that the hypotriglyceridemic effect of a high-MUFA diet may be attributable in part to a reduced hepatic production of apoC-III.
Introduction
Apolipoprotein (apo) C-III has been shown to be an independent predictor of recurrent coronary events (Sacks et al., 2000) and a powerful, significant marker of prevalent coronary heart disease (CHD) in men, independent of lowdensity lipoprotein (LDL)-cholesterol (C) and high-density lipoprotein (HDL)-C (Onat et al., 2003) . These associations may reflect the important role played by apoC-III in regulating the metabolism of plasma triglyceride-rich lipoproteins (TRL). Proposed mechanisms underlying the hypertriglyceridemic effect of apoC-III comprise inhibition of lipoprotein lipase activity (Wang et al., 1985) and lower clearance of TRL by hepatic lipoprotein receptors (Windler and Havel, 1985) . Elevated plasma triglyceride is one of the key components of the metabolic syndrome, a clinical clustering of cardiovascular risk factors affecting nearly 25% of the US adult population (Ford et al., 2002) . Moderate hypertriglyceridemia is also recognized as an independent risk factor for coronary events (Austin, 1999) . A better prevention of CHD requires a thorough understanding of the mechanisms responsible for the regulation of plasma TG concentrations.
Recent kinetic studies conducted in humans have suggested that an increased production rather than a decreased catabolism of apoC-III was the most important determinant of plasma TG levels in human subjects and a characteristic feature of patients with hypertriglyceridemia (Cohn et al., 2004b) . These results suggest that a pharmacological or dietary treatment that reduces apoC-III production would most likely be effective in lowering plasma TG levels.
Only a limited number of studies have investigated the impact of nonpharmacological treatments such as diet on plasma apoC-III metabolism and concentration (Huff and Nestel, 1982; Malmendier et al., 1989) . We have recently shown that when consumed under ad libitum conditions, a high-fat diet rich in monounsaturated fatty acid (MUFA) significantly reduced plasma TG and apoC-III levels, whereas a low-fat control diet had no significant impact on these variables (Archer et al., 2003a (Archer et al., , 2005 . The mechanisms whereby variations in plasma apoC-III concentrations may be related to the hypotriglyceridemic effect of the high-MUFA diet remain to be investigated. Therefore, the objective of this study was to investigate the impact of a high-MUFA diet on plasma apoC-III metabolism and to examine how these changes predicted concurrent variations in plasma TG levels.
Subjects and methods

Study design
This two-arm parallel study has been described in detail previously (Archer et al., 2003a) . Briefly, 65 men, of which 18 participated in the kinetic study (Desroches et al., 2004) , were recruited in the Québec metropolitan area. Participants were recruited to cover a wide range of adiposity, and had to be nonsmokers and free of any endocrine, cardiovascular, hepatic or renal disorders. Subjects using medication likely to interfere with lipid metabolism at the time of screening were excluded. Individuals with unusual dietary habits such as vegetarianism, food aversions or allergies and those who had experienced a significant weight change within the year that preceded study onset were also excluded. Each participant signed a consent form approved by the Laval University Ethics Committee. Subjects were randomly assigned to either a high-fat diet rich in MUFA or a low-fat control diet, which they consumed ad libitum for 6-7 weeks. Participants and laboratory technicians were blinded to dietary assignments.
Experimental diets
The low-fat control diet (58% carbohydrate, 16% protein and 26% fat) and the high-MUFA diet (45% carbohydrate, 15% protein and 40% fat of which 450% were derived from MUFA) were constituted of food prepared daily in the metabolic kitchen and weighed in individual portions. Both diets consisted of the same meals, which differed mainly in the amount of fat and carbohydrate provided. The nutritional composition of the experimental diets was assessed with the Canadian Nutrient File database (Health Canada, Ottawa, 1997) 
Dietary intervention
On weekdays, subjects came to the metabolic unit to consume their lunch meal and were given their next dinner and breakfast meals packaged to take home. Weekend meals were given to the participants on Fridays. To achieve ad libitum conditions, subjects were provided with food representing 150% of their usual daily energy intake as assessed by a 3-day food record (2 weekdays and 1 weekend day) obtained at baseline. Uneaten portions had to be returned to the metabolic unit for measurement of actual energy intake. Subjects were asked to restrict their intake of caffeinecontaining beverages to o2 per day, but had free access to water and to diet/caffeine-free soft drinks. As indicated previously, compliance to the diet was judged to be excellent (Archer et al., 2003a) .
Anthropometric measurements
Body weight and waist circumference were measured according to standardized procedures (Lohman et al., 1988) .
Laboratory methods
At the beginning and end of the study, plasma lipid and lipoprotein levels were measured after a 12-h fasting period, as described previously (Archer et al., 2003a) . Plasma fasting apoC-II and apoC-III concentrations were measured by nephelometry (BN-100, Dade-Behering, Marburg, Germany) using polyclonal antibodies against human apoC-II and apoC-III, respectively (Kamiya Biomedical Co., Seatle, WA, USA). Intra-and interassay coefficients of variation for this measurement were both p6.0%, as described previously (Couillard et al., 2003) . Distinct subpopulations of LDL particles in whole plasma were separated by size using a nondenaturing 2-16% gradient gel electrophoresis, as described previously (St Pierre et al., 2001; Archer et al., 2003b) . Postheparin (60 IU/kg body weight) lipoprotein lipase (LPL) and hepatic lipase (HL) activities were measured after preincubation with sodium dodecyl sulfate (SDS), as previously described (Watson et al., 1995; Bower et al., 2002) .
Kinetic studies
Kinetic studies were performed at the beginning and end of the dietary interventions using a primed constant infusion of [5, 5, H 3 ]L-leucine, as described previously (Desroches et al., 2004) . Briefly, after a 12 h fast, kinetic subjects were fed cookies (65% carbohydrate, 20.2% lipids and 14.5% protein) every 30 min for 15 h. Each half-hourly portion represented 1/30th of their daily energy requirements. Three hours after the first half-hourly meal, subjects received an intravenous bolus dose of 10 mmol/kg [5, 5, H 3 ]L-leucine, which was subsequently followed by a constant infusion at 10 mmol/kg/h. Throughout the infusion, blood samples were collected by a second intravenous line into Vacutainer tubes containing ethylenediaminetetraacetic (EDTA) at 0, 0.25, 0.50, 1, 2, 3, 4, 6, 8, 10 and 12 h. We have recently shown that this fed-state kinetic protocol allowed study participants to achieve steadystate rapidly, with plasma TG concentrations being maintained throughout the infusion period (Tremblay et al., 2004) .
Isotopic enrichment measurement
ApoC-III occurs in plasma as three different isoforms, which differ by their degree of syalilation (0, 1 or 2). ApoC-III 1 is generally the most abundant isoform and has been used in most previous studies of apoC-III kinetics in the past. ApoC-III in the present study refers to the apoC-III 1 isoform. ApoC-III was isolated from the do1.25 g/ml plasma fraction obtained after centrifugation of whole plasma for 48 h at 50 000 r.p.m at 41C in a Beckman 50.4 Ti rotor. Infranatant was then dialysed overnight in an NaCl-Tris base-EDTA buffer, incubated with cysteamine for 4 h at 371C and delipidated using acetone-ethanol and diethyl ether, as described previously ). ApoC-III was then separated using preparative isoelectric focusing (IEF) on polyacrylamide-urea gels (pH gradient 4-7). Very-lowdensity lipoprotein (VLDL) apoB-100 (do1.006 g/ml) was separated by SDS-polyacrylamide gel electrophoresis (PAGE) according to standardized procedures (Kotite et al., 1995) , as described previously (Mauger et al., 2005) . Protein bands on IEF and SDS polyacrylamide gels revealed with Coomassie blue were excised and hydrolyzed with 6 N HCl and incubated at 1101C for 24 h. Free amino acids in the hydrolysate were purified by cation-exchange chromatography and derivatized by adding propanol/acetyl chloride and heptafluorobutyric anhydride reagents. Samples were then analyzed using a gas chromatograph-mass spectrometer (GCMS) (GC 6890N, MS 5973N Agilent Technologies, Palo Alto, CA, USA). Identification of labeled and unlabeled leucine was made by methane-negative chemical ionization.
Selective ion monitoring at m/z ¼ 352/349 was used to determine the tracer/tracee ratio, which was calculated using the formula described previously (Cobelli et al., 1992) .
Kinetic analyses
ApoC-III and VLDL apoB-100 fractional catabolic rates (FCR) were determined by fitting the tracer to tracee ratios to a monoexponential function. Using SAAM II software (University of Washington, Department of Bioengineering, Seattle, WA, USA), data were fitted to the mathematical function Z(t) ¼ Z p (1Àe Àk(tÀd) ), where Z(t) is the tracer to tracee ratio at time t, Z p is the tracer to tracee ratio corresponding to the plateau of the curve representing the precursor amino-acid pool, d is the delay time in hours and k is the FCR in pools per hour. The VLDL apoB-100 enrichment plateau was used as the forcing function for apoC-III precursor pool enrichment. The absolute production rate (PR) was calculated (in mg/kg/day) using the formula PR ¼ FCR ðpools=dayÞ Â plasma apoC À III pool size ðmgÞ body weight ðkgÞ Pool size (PS) was calculated as the plasma apoC-III concentration (mg/l) multiplied by plasma volume (value fixed at 0.045 l/kg body weight).
Statistical analyses
Data were analyzed using SAS (version 8.2; SAS Institute Inc., Cary, NC, USA). The significance of the differences within and between dietary groups was assessed with the MIXED procedure for repeated measures using the least-square means test. Plasma apoC-III PS and FCR and fasting plasma TG, VLDL-TG, VLDL-C, apoCII and apoCIII levels and HL and LPL activities were log transformed to normalize their distribution before statistical analysis. Correlation analyses were conducted using Spearman rank correlations.
Results
Diet-induced changes in plasma lipid and apo levels in the entire study group of 65 subjects have been presented elsewhere (Archer et al., 2003a (Archer et al., , b, 2005 . Baseline characteristics of participants assigned to each dietary protocol were comparable except for the age of participants in the kinetic subsample, who were older in the high-MUFA diet group than in the low-fat control group. In the kinetic subgroup of 18 men, changes induced by both dietary treatments on plasma lipid and lipoprotein levels were essentially similar in magnitude to those observed in the entire study group (Desroches et al., 2004) . The low-fat control diet-induced reductions in total-C, LDL-C and HDL-C concentrations. The high-MUFA diet induced significant reductions in total-C, LDL-C and plasma TG. In the high-MUFA group, although reductions in VLDL-C, VLDL-TG and apoC-III concentrations were similar in magnitude in the 18 kinetic subjects to those previously reported in the entire study sample of 65 subjects, they did not reach statistical significance in this smaller subset of subjects (Tables 1 and 2 ). Both diets induced moderate but statistically significant reductions in body weight and waist circumference, which were comparable between the low-fat control diet and the high-MUFA diet (data not shown) (Desroches et al., 2004) .
The low-fat control diet had no significant impact on apoC-III kinetics ( Table 2 ). The high-MUFA diet led to a significant 16.4% reduction in plasma apoC-III PS (Po0.05). Although the high-MUFA diet led to a reduced plasma apoC-III PR in six out of eight subjects, the 8.8% mean reduction did not reach statistical significance. Adjusting the statistical model for age had no impact on the between-diet comparison of kinetic data (data not shown).
In the low-fat control group, correlation analyses revealed statistically significant positive relationships between dietinduced changes in the PS of apoC-III and changes in plasma levels of TG (r ¼ 0.67, Po0.05), LDL-C (r ¼ 0.65, Po0.05), VLDL-C (r ¼ 0.64, Po0.05) and VLDL apoB-100 (r ¼ 0.81, Po0.01), and a negative association with variations in LDL peak particle size (r ¼ À0.71, Po0.05). Adjusting these correlations for diet-induced changes in body weight or in body mass index attenuated correlations pertaining to plasma TG, LDL-C and VLDL-C levels (P-value 0.08-0.26) but not VLDL apoB-100 concentrations. In the high-MUFA group, diet-induced variations in plasma apoC-III PS were significantly associated with variations in plasma apoC-III PR (r ¼ 0.74, Po0.05) but not apoC-III FCR (r ¼ 0.33, P ¼ 0.42). Changes in apoC-III PR were also significantly associated with changes in plasma TG (r ¼ 0.85), VLDL-TG (r ¼ 0.81, Figure 1 ), VLDL-C (r ¼ 0.86) and VLDL apoB-100 levels (r ¼ 0.81, Figure 1 ) (Po0.05 for all). Changes in plasma apoC-III and TG remained strongly correlated after statistical adjustment for changes in VLDL apoB PR (r ¼ 0.83, Po0.05). A positive correlation was also observed between dietinduced variations in plasma apoC-III PR and VLDL apoB-100 PR, although the relationship did not achieve statistical significance in these eight subjects (r ¼ 0.69, P ¼ 0.06, Figure 1 ). There was no correlation between plasma apoC-III PR and VLDL apoB-100 FCR (r ¼ 0.40, P ¼ 0.32) in the high-MUFA group. All of these associations found within the high-MUFA group were virtually unaltered by statistical adjustments for diet-induced changes in anthropometric variables (data not shown).
Multiple regression analyses in all 18 kinetic subjects showed that diet-induced variations in plasma apoC-III PR accounted for more than 30% (Po0.01) of the diet-induced changes in plasma TG (Table 3) in a model that included age, plasma TG before the dietary intervention, experimental dietary group (low-fat control vs high MUFA), diet-induced variations in body weight, plasma apoC-III FCR, LPL and HL activities, and energy intake before and on the experiment. In a model that included age at baseline and diet-induced changes in percent energy from MUFA (on diet vs baseline), HOMA IR homeostasis model assessment, VLDL apoB-100 PR and body weight, the change in the proportion of energy from MUFA was the strongest correlate of the diet-induced variation in plasma apoC-III PR (shared variance 20.2%, P ¼ 0.06).
Discussion
This study provides novel information regarding the impact of a high-MUFA diet consumed under unrestricted energy intake on plasma apoC-III metabolism and how it modulates diet-induced variations in plasma TG and apoC-III concentrations. The low-fat control diet had no effect on apoC-III kinetics, which partly explains the lack of effect of that diet on plasma TG and apoC-III concentrations previously observed (Archer et al., 2003a (Archer et al., , 2005 . The relatively strong correlations between variations in apoC-III PS induced by consumption of the low-fat control diet and concurrent variations in plasma levels of TG, LDL-C, VLDL-C, VLDL apoB-100 as well as in LDL peak particle size indicated that apoC-III may be a key determinant of the dietary effect on these variables, as we have previously reported (Archer et al., 2005) . On the other hand, a significant reduction in apoC-III PS, which correlated with changes in apoC-III PR, was found within the high-MUFA group. Although the reduction in apoC-III PS was not paralleled by significant changes in plasma apoC-III PR or FCR, the 8.8% reduction in apoC-III PR and 7.3% increase in apoC-III FCR may have been responsible, in combination, for the resulting 15-16% Figure 1 Relationship between changes in apoC-III PR and changes in plasma VLDL-TG, VLDL apoB-100 levels and VLDL apo B-100 PR induced by the low-fat control diet (left panels) and the high-MUFA diet (right panels).
reduction in plasma apoC-III concentrations and PS. Finally, correlation analyses showed that variation in plasma apoC-III PR induced by the high-MUFA diet was a strong correlate of diet-induced changes in plasma TG, apoC-III, VLDL-C, VLDL-TG, VLDL apoB-100 levels and of VLDL apoB-100 PR.
To our knowledge, only two studies using radiolabeling methodology have investigated the impact of diet on apoC-III metabolism to date. An earlier study was conducted by Huff and Nestel (1982) to determine simultaneous kinetics of apoC-II, C-III 1 and C-III 2 following injection of 125 I-VLDL in six men consuming a high-fat control diet (39% carbohydrate, 14% protein and 47% fat) or a high-carbohydrate diet (68% carbohydrate, 14% protein and 18% fat). The isocaloric high-carbohydrate diet led to increased plasma TG concentrations and a significant increase in the mass of apoC-II, C-III 1 and C-III 2 , attributable to an increase in production rather than to a decrease in catabolism. Our results concur with these data in that the lack of change in plasma TG and apoC-III concentrations with the ad libitum consumption of the low-fat control diet mirrored the absence of change in apoCIII metabolism. Malmendier et al. (1989) investigated the effect of a combined treatment comprising a restricted hypocaloric diet limited in fat and 300 mg fenofibrate daily on the kinetics of 131 I-apoC-III in four hypertriglyceridemic men. After 1 month of treatment, reductions in plasma TG and apoC-III levels (À56 and À48%, respectively) were observed, which were associated with an increase in apoC-III catabolism and a decrease in apoC-III production. Because a combined treatment was used, the authors were not able to differentiate which of the diet and the fenofibrate treatment was responsible for the observed effects (Malmendier et al., 1989) . Studies have demonstrated that the hypotriglyceridemic effect of fibrates was mediated in part via the peroxisome proliferator-activated receptors (PPAR)-a through the inhibition of apoC-III gene transcription and the upregulation of the LPL gene (Schoonjans et al., 1996) . This may explain part of the results obtained by Malmendier et al. (1989) . Although data concerning the modulating impact of dietary factors on gene expression are still scarce, they are the focus of increasing interest. In vitro studies have demonstrated that polyunsaturated fatty acids (PUFA), and to a lesser extent MUFA, can function as ligands for PPAR-a (Kliewer et al., 1997) . In an earlier study, Brousseau et al. (1995) reported that both a high-MUFA diet and a high-PUFA diet were associated with lower hepatic apoC-III mRNA when compared to a high saturated fat diet in cynomolgus monkeys. Accordingly, our results also indicated that dietinduced change in intake of MUFA (on diet vs baseline) was associated with the changes in plasma apoC-III PR. Although these observations suggest that the hypotriglyceridemic effect of the high-MUFA diet in the present study may be partly attributable to the modulation of apoC-III gene expression by MUFAs, further studies are clearly warranted to confirm this hypothesis in humans.
Recent kinetic studies reported a close relationship between plasma or VLDL apoC-III and VLDL apoB kinetics in overweight or obese men (Chan et al., 2002; Cohn et al., 2004a) . Chan et al. (2002) reported that plasma concentrations of apoC-III were positively associated with VLDL apoB PR and inversely associated with VLDL apoB FCR. Results from Cohn et al. indicated that plasma and VLDL apoC-III production were strongly correlated with the plasma concentration as well as production of VLDL-TG. Our data are in agreement with these observations. Indeed, we have shown significant and positive correlations between diet-induced variation in plasma apoC-III PR and concurrent change in plasma TG, apoC-III, VLDL-C, VLDL-TG and VLDL apoB-100 PR in the high-MUFA group. Nevertheless, additional in vitro studies are required to establish a cause and effect relationship between apoC-III and VLDL production. We hypothesize that the lack of a statistically significant correlation between the PRs of VLDL and apoC-III after the low-fat control diet may be attributable to diverging effects of the low-fat control diet per se on these two mechanisms, and the small but significant effect of weight loss on both apoC-III and VLDL apoB-100 PR. No significant correlation was found between plasma apoC-III PR and VLDL apoB-100 FCR, which was rather surprising considering that apoC-III inhibits LPL activity and clearance of TG-rich lipoproteins (Wang et al., 1985; Windler and Havel, 1985) . The inverse correlation between VLDL or plasma apoC-III PR and VLDL apoB-100 FCR has been observed in some (Chan et al., 2006) but not all studies (Cohn et al., 2004a) . Reasons for these diverging results include differences in subjects' characteristics, in the kinetic study protocol, in the sample size and in the experimental design. Indeed, our study was the only one to look at longitudinal associations along with a diet effect. It is therefore possible that the intervention per se may have blunted the association between apoC-III PR and VLDL apoB-100 FCR.
The multiple linear regression analyses conducted in the present study showed that plasma apoC-III PR was the most significant determinant of diet-induced changes in plasma Kinetics of plasma apolipoprotein C-III metabolism S Desroches et al TG levels. In these analyses, the experimental dietary group (high MUFA vs low-fat control) was not an independent predictor of the change in TG levels. This may seem inconsistent with the fact that the two diets had significantly different effects on plasma TG levels (Archer et al., 2003a) . We rather believe that our results further support the concept that the differential impact of the two diets on TG levels was primarily attributable to their variable effects on apoC-III metabolism. The modest but significant reduction in body weight induced by both dietary interventions in the context of this ad libitum feeding study may be rightfully perceived as a potential modulator of the diet-induced changes in TG levels. However, we have previously shown that changes in lipid and lipoprotein levels induced by the high-MUFA diet were independent of changes in body weight and body composition, whereas improvements in plasma lipids induced by the ad libitum consumption of a low-fat control diet were partly mediated by changes in body weight (Archer et al., 2003a) . Accordingly, despite the limited sample of subjects of the present study, when correlations were adjusted for diet-induced changes in anthropometric measures, variations in apoC-III PR remained a strong correlate of the changes in TG and VLDL-TG associated with consumption of the high-MUFA diet, but not in the low-fat control group.
Limitations of the present study must be addressed. First, it must be acknowledged that a crossover study design may have allowed us to better appreciate the between-diet differences in the kinetics of the various apolipoproteins, mainly because of the increased statistical power it would have provided. However, the ad libitum nature of the study, which purposefully led to significant variations in body weight, would have made such a design rather complex. Second, given the differential impact of the experimental diets on plasma TG and HDL-C concentrations, studying VLDL and HDL apoC-III kinetics may have provided interesting complementary information. These include potential diet-specific redistributions of apoC-III from VLDL to HDL resulting in modifications of the metabolic fate of plasma lipoproteins. Irrespective of these considerations, the reduction in apoC-III PR remains a strong correlate of changes in plasma TG and apoC-III within the high-MUFA group.
This study documented for the first time the impact of a high-MUFA diet consumed under ad libitum conditions on in vivo apoC-III kinetics. In summary, we have shown that in the high-MUFA dietary group, variations in apoC-III PR predicted diet-induced changes in VLDL levels. Consumption of the low-fat control diet, even in the presence of weight loss, had no significant impact on mean plasma apoC-III kinetics, although changes in apoC-III PS were predictors of plasma changes in TG, LDL-C, VLDL-C and VLDL apoB-100 concentrations. Together with our previous results having shown that a high-MUFA diet induced a reduction in plasma TG and apoC-III concentrations, our data suggest that the hypotriglyceridemic effect of the high-MUFA diet may be attributed in part to a reduced production of apoCIII.
